Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Penumbra, Inc.

Revenue

Revenue %Chg

Revenue Common Size

Cost of Revenue

Cost of Revenue %Chg

Cost of Revenue Common Size

Gross Profit

Gross Profit %Chg

Gross Profit Common Size

Research and Development

Research and Development %Chg

Research and Development Common Size

Sales, General and Administrative

Sales, General and Administrative %Chg

Sales, General and Administrative Common Size

Acquired in-Process Research and Development

Acquired in-Process Research and Development %Chg

Acquired in-Process Research and Development Common Size

Impairment Charge

Impairment Charge %Chg

Impairment Charge Common Size

Total Operating Expenses

Total Operating Expenses %Chg

Total Operating Expenses Common Size

Income from Operations

Income from Operations %Chg

Income from Operations Common Size

Interest Income (Expense), Net

Interest Income (Expense), Net %Chg

Interest Income (Expense), Net Common Size

Other Income, Net

Other Income, Net %Chg

Other Income, Net Common Size

Interest and Other Income, Net

Interest and Other Income, Net %Chg

Interest and Other Income, Net Common Size

Other Expense, Net

Other Expense, Net %Chg

Other Expense, Net Common Size

Income Before Income Taxes

Income Before Income Taxes %Chg

Income Before Income Taxes Common Size

Provision for Income Taxes

Provision for Income Taxes %Chg

Provision for Income Taxes Common Size

Income Before Equity in Losses of Unconsolidated Investee

Income Before Equity in Losses of Unconsolidated Investee %Chg

Income Before Equity in Losses of Unconsolidated Investee Common Size

Equity in Losses of Unconsolidated Investee

Equity in Losses of Unconsolidated Investee %Chg

Equity in Losses of Unconsolidated Investee Common Size

Net Income

Net Income %Chg

Net Income Common Size

Net Income Attributable to Common Stockholders

Net Income Attributable to Common Stockholders %Chg

Net Income Attributable to Common Stockholders Common Size

Net Loss Attributable to Non-Controlling Interest

Net Loss Attributable to Non-Controlling Interest %Chg

Net Loss Attributable to Non-Controlling Interest Common Size

Net Income Attributable to Penumbra, Inc.

Net Income Attributable to Penumbra, Inc. %Chg

Net Income Attributable to Penumbra, Inc. Common Size

Basic

Basic %Chg

Basic Common Size

Diluted

Diluted %Chg

Diluted Common Size

Total Revenues

Total Revenues %Chg

Total Revenues Common Size

Cost of Sales

Cost of Sales %Chg

Cost of Sales Common Size

Gross Profit Margin

Gross Profit Margin %Chg

Gross Profit Margin Common Size

Selling, General & Administrative Expenses

Selling, General & Administrative Expenses %Chg

Selling, General & Administrative Expenses Common Size

Research & Development Expenses

Research & Development Expenses %Chg

Research & Development Expenses Common Size

Other Operating Expenses

Other Operating Expenses %Chg

Other Operating Expenses Common Size

Operating Profit

Operating Profit %Chg

Operating Profit Common Size

Operating Margin

Operating Margin %Chg

Operating Margin Common Size

Non-Operating Income

Non-Operating Income %Chg

Non-Operating Income Common Size

Total Non-Operating Income

Total Non-Operating Income %Chg

Total Non-Operating Income Common Size

Income Before Provision for Income Taxes

Income Before Provision for Income Taxes %Chg

Income Before Provision for Income Taxes Common Size

Consolidated Net Income

Consolidated Net Income %Chg

Consolidated Net Income Common Size

Net Income Attributable to Minority Interests and Other

Net Income Attributable to Minority Interests and Other %Chg

Net Income Attributable to Minority Interests and Other Common Size

Net Income Attributable to Common Shareholders

Net Income Attributable to Common Shareholders %Chg

Net Income Attributable to Common Shareholders Common Size

Basic EPS

Basic EPS %Chg

Basic EPS Common Size

Diluted EPS

Diluted EPS %Chg

Diluted EPS Common Size

Basic Weighted Average Shares Outstanding

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Adjusted Net Income

Net Revenue

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Income Statement	Jun '25	Dec '24	Jun '24	Dec '23	Jun '23	Dec '22
Total Revenues	663.6	616.6	578.1	555.6	502.9	434.9
Total Revenues %Chg	14.8%	11%	14.9%	27.8%	22%	10.3%
Revenue
Cost of Sales	223.7	205.5	234.1	190.9	185	161.1
Cost of Revenue
Gross Profit	439.9	411	344	364.7	317.9	273.8
Gross Profit Margin	66.3%	66.7%	59.5%	65.6%	63.2%	62.9%
Selling, General & Administrative Expenses	313.4	287.7	286.3	255.9	250.5	224.2
Sales, General and Administrative
Research & Development Expenses	45.3	45.2	49.6	61.1	41.5	39.3
Research and Development
Acquired in-Process Research and Development
Other Operating Expenses	—	—	76.9	—	—	—
Impairment Charge
Operating Profit	81.2	78.1	-68.9	47.7	25.9	10.3
Operating Margin	12.2%	12.7%	-11.9%	8.6%	5.1%	2.4%
Non-Operating Income	8	6	5.6	3.8	2.3	-0.1
Interest Income (Expense), Net
Other Income, Net
Other Expense, Net
Interest and Other Income, Net
Total Non-Operating Income	8	6	5.6	3.8	2.3	-0.1
Income Before Provision for Income Taxes	89.2	84.1	-63.2	51.5	28.2	10.2
Provision for Income Taxes	4.7	20.9	-14.1	-12	0.7	8.6
Provision for Income Taxes
Consolidated Net Income	84.5	63.2	-49.2	63.4	27.5	1.6
Net Income Attributable to Minority Interests and Other	—	—	—	—	—	—
Equity in Losses of Unconsolidated Investee
Net Loss Attributable to Non-Controlling Interest
Net Income Attributable to Common Shareholders	84.5	63.2	-49.2	63.4	27.5	1.6
Net Income Attributable to Common Stockholders
Net Income Attributable to Penumbra, Inc.
Basic EPS	2.2	1.6	-1.3	1.7	0.7	0.1
Diluted EPS	2.2	1.6	-1.3	1.6	0.7	0.1
Basic Weighted Average Shares Outstanding	38.7	38.5	38.8	38.5	38.3	38
Total Shares Outstanding	39	38.5	38.8	38.7	38.4	38.1
Diluted Weighted Average Shares Outstanding	39.2	39.8	38.8	39.3	39.2	38
EBITDA	91.7	86.7	-53.7	61.6	39.2	22.9
Effective Tax Rate	5.2%	24.9%	22.2%	-23.3%	2.4%	84.2%